SonALAsense
SonALAsense is a clinical-stage company developing ALA sonodynamic therapy (SDT) as a first-in-class, non-invasive drug-device combination for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. SDT utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to target and kill tumor cells selectively.
Latest SonALAsense Content
Product News
FDA Grants Fast Track Designation to SonALAsense’s SONALA-001
Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.
Industry Insight
A Non-Invasive Treatment for Difficult-To-Treat Pediatric Brain Cancer
In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.
Product News
SonALAsense Announces Completion of First Cohort in Phase 2 Study of Sonodynamic Therapy for Recurrent Glioblastoma
SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled.
Product News
SonALAsense Forges Ahead With First Patient Dosing for Devastating Childhood Brain Cancer
Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
Advertisement
